IRVINE, Calif., Feb. 24 /PRNewswire-FirstCall/ -- Endologix, Inc. , developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the ROTH 22nd Annual OC Growth Stock Conference at The Ritz-Carlton Hotel in Laguna Niguel, CA.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.
CONTACT: John McDermott, CEO, Endologix, Inc., +1-949-595-7200; or
Investors, Nick Laudico, +1-646-536-7030 or Zack Kubow, +1-646-536-7020,
both of The Ruth Group
Web site: http://www.endologix.com/
